TRDA

Entrada Therapeutics, Inc.

13.22 USD
-0.51 (-3.71%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Entrada Therapeutics, Inc. stock is down -10.19% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 March’s closed higher than February.

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for Duchenne muscular dystrophy and myotonic dstrophy type 1.